Liraglutide dosing & administration
FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
0.6 mg
Frequency
Once daily
Duration
Week 1
FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation [6].
1.2-1.8 mg
Frequency
Once daily
Duration
Ongoing
Victoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control is needed [6].
3.0 mg
Frequency
Once daily
Duration
Ongoing
Saxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) [6].
Timing
Best time to take
Administer Liraglutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Liraglutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Liraglutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Liraglutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Liraglutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Liraglutide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Diarrhea, Vomiting, Decreased appetite and headache
Less common: Injection site reactions
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Liraglutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Liraglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- Other GLP-1 receptor agonists (semaglutide, exenatide, dulaglutide) — redundant mechanism with increased adverse effects and no additional benefit — Use with caution—discuss with your healthcare provider.
- DPP-4 inhibitors (sitagliptin, saxagliptin) — overlapping incretin pathway mechanism; inferior to liraglutide monotherapy in head-to-head trials — Use with caution—discuss with your healthcare provider.
- Sulfonylureas at full dose — increased hypoglycemia risk requires 50% sulfonylurea dose reduction when adding liraglutide — Use with caution—discuss with your healthcare provider.
Published research
What the studies show
Peng ZY, Lee YH, Ou HT · 2025
Liraglutide's heart benefits work through multiple pathways: HbA1c reduction (38%), improved kidney function (18%), and blood pressure lowering (7%) in diverse patient groups.
Hamed K, Alosaimi MN, Ali BA · 2024
Research (2024) on liraglutide contributes important scientific knowledge about its biological and pharmacological properties.
Xie Z, Hu J, Gu H · 2023
Research (2023) demonstrates liraglutide's efficacy in clinical treatment and therapeutic applications.
Ali AM, Martinez R, Al-Jobori H · 2020
Clinical evidence (2020) supports the therapeutic use of liraglutide in medical treatment protocols.
Ryan GJ, Hardy Y · 2011
Clinical evidence (2011) supports the therapeutic use of liraglutide in medical treatment protocols.
Novo Nordisk · 2023
FDA label: starting dose 0.6 mg once daily SC, escalated 0.6 mg weekly to a 3.0 mg maintenance dose for chronic weight management; Victoza maintenance 1.2-1.8 mg for type 2 diabetes.
Head to head
Liraglutide compared
Studied for
Conditions Liraglutide has been researched in
Want the full picture?
The complete Liraglutide research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.